Calverley P, Rogliani P, Papi A
Disclosure of interest: Elisabeth Hofstaetter: Medical Lead of Novartis Pharma GmbH, All other authors: nothing to disclose Poster Session I - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P389 - ESOC25-2231 ADDRESSING GENDER DISPARITIES IN CEREBROVASCULAR CLINICAL TRIALS: BARRIERS AND STRATEGIES FOR INCLUSION Virginia Cancelloni 1 , Victoria Rcker 2 , Kirsten Harvey 3 , Kirsten Haas 2 , Peter Heuschmann 2 , Bianca Koehler 1 , Mara Graziani 1 , Roland Veltkamp 3,4 , Valeria Caso 1 1 Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy, 2 Institute of Clinical Epidemiology and Biometry, University of Wrzburg, Wrzburg, Germany, 3 Department of Brain Sciences, Imperial College London, London, United Kingdom, 4 Department of Neurology, Alfried Krupp Krankenhaus Essen, Essen, Germany Background and Aims: The underrepresentation of women in cerebrovascular randomised control trials (RCTs) remains a pressing issue
Complete Your Medical Questionnaire After placing your order, youll complete a short medical intake outlining your health history
Can stage 3 lipedema be reversed
Discussion: Our findings demonstrate that PT delays dermal senescence by enhancing mitochondrial quality via enhancing mitophagy
The Test-Tube Synthesis of a Chemical Called Poliovirus
